Term
|
Definition
· relieves AMPA receptor desensitization but does not affect kainate receptors. (Makes AMPA work) |
|
|
Term
|
Definition
| relieves desensitization of kainate receptors but has insignificant effects on AMPA. (Makes Kainate work) |
|
|
Term
|
Definition
| A partial agonist that binds to glycine site on the NMDA receptor (used to enhance effects of antipsychotics in schizophrenia). |
|
|
Term
|
Definition
| These drugs bind at the Mg2+ binding site and are noncompetitive receptor antagonists. They occlude the receptor similar to Mg2+. (LOW DOSE PSYCHOTOMIMETIC, HIGH DOSE DISSOCIATIVE ANALGESIC) |
|
|
Term
|
Definition
| These drugs bind at the Mg2+ binding site and are noncompetitive receptor antagonists. They occlude the receptor similar to Mg2+. (LOW DOSE PSYCHOTOMIMETIC, HIGH DOSE DISSOCIATIVE ANALGESIC) |
|
|
Term
|
Definition
| Anticonvulsant drug, also act at GAT-1 transporter. |
|
|
Term
|
Definition
antidepressant, inhibit all subtypes of GABA transporters;however they have much lower affinity for GABA transporters compared to norepinephrine transporters. |
|
|
Term
|
Definition
antidepressant, inhibit all subtypes of GABA transporters;however they have much lower affinity for GABA transporters compared to norepinephrine transporters. |
|
|
Term
|
Definition
| antidepressant, blocks transport through both GAT-1 and GAT-3 with an affinity of 10 times lower than that for the serotonin transporter. |
|
|
Term
|
Definition
| binds to GABA , ANTAGONIST, used for sleep apnia, insomnia, anxiety disorders |
|
|
Term
|
Definition
| bind to GABAb, agonist, used for sleep apnia, insomnia, anxietydisorders, works to help trigeminal neuralgia by disinhibiting |
|
|
Term
|
Definition
| bind to GABAb, antagonist, used for sleep apnia, insomnia, anxiety disorders |
|
|
Term
|
Definition
| used for insomnia (e.g., Ambien) |
|
|
Term
|
Definition
| tranquilizer (e.g., Valium) |
|
|
Term
|
Definition
MAO inhibitors, are used clinically to treat depression and
Parkinson disease, panic disorder. |
|
|
Term
|
Definition
MAO inhibitors, are used clinically to treat depression and
Parkinson disease, panic disorder. |
|
|
Term
|
Definition
| used for treatment of TB, causes hepatitis as adverse side effect). MAOs |
|
|
Term
Catechol-o-methyl transferase (COMT) |
|
Definition
Catabolizes catecholamines present at the synaptic cleft. COMT methylates catecholamines, and for that requires S-adenosyl-methionine as methyl donor.
|
|
|
Term
|
Definition
blocks a2-adrenergic receptors, and by inhibiting autoreceptors, can increase NE
neurotransmission. |
|
|
Term
|
Definition
| blocks VMATs and inhibits catecholamine uptake into vesicles (antihypertensive, antipsychotic) |
|
|
Term
|
Definition
| are used in hypertension. a2- antagonists are also used to treat physical withdrawal from opiates, effect mediated by receptors in the LC. |
|
|
Term
|
Definition
a non selective b-AR antagonist is used for social phobia or anxiety disorder. |
|
|
Term
|
Definition
| is the rate limiting step for serotonin synthesis |
|
|
Term
|
Definition
| Tricyclic antidepressant , also has high affinity for SERT. |
|
|
Term
|
Definition
reversible anticholinesterases , which can inactivate AChE
for 4 hrs, used for treating myasthenia gravis. |
|
|
Term
|
Definition
reversible anticholinesterases , which can inactivate AChE
for 4 hrs, used for treating myasthenia gravis. |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| Muscarinic receptor antagonists |
|
|
Term
|
Definition
| Muscarinic receptor antagonists |
|
|
Term
|
Definition
| inhibits vesicular transport of ACh, and depletes ACh from vesicles. |
|
|
Term
|
Definition
| cause paralysis by preventing ACh release from motor neuron terminals. |
|
|
Term
|
Definition
| cause paralysis by preventing ACh release from motor neuron terminals. |
|
|
Term
|
Definition
| promotes massive vesicular release of Ach |
|
|
Term
|
Definition
| Choline transport inhibitors , can be used to deplete neuronal stores of ACh. |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| inhibits vesicular transport of Acetylcholine |
|
|
Term
|
Definition
| Muscarinic receptor antagonist |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| nonspecific blocker of nAChR |
|
|
Term
|
Definition
| inverse agonist at BZ site, anxiogenic |
|
|
Term
|
Definition
| PTSD Beta adrenergic antagonist |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| blocks CL- channel, convulsent |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| partial 5HT agonist, anxiolytic, less addiction |
|
|
Term
| Adenosine Receptor Agonist |
|
Definition
| inhibits monoamines, sedative, anxiolytic, analgesic |
|
|
Term
|
Definition
| Adenosine receptor antagonist |
|
|
Term
|
Definition
|
|
Term
|
Definition
| antagonist to 5HT, alpha 2 adrenergic receptors |
|
|
Term
|
Definition
| NRI, less side effects than tricyclics |
|
|
Term
|
Definition
| Starts off antidepressant, than stops, depletes monoamines |
|
|
Term
|
Definition
| alpha 2 adrinergic antagonist |
|
|
Term
|
Definition
| enhance LTP, partial agonist to glycine, enhance antipsychotics |
|
|
Term
|
Definition
|
|
Term
|
Definition
| impaires anesthesia and reduces adgitation, antipsychotic |
|
|
Term
|
Definition
| antipsychotic, hypertension, block VMAT, inhibits catacholamine uptake in vesicles |
|
|
Term
|
Definition
| most extraparietal side effects, antipsychotic |
|
|
Term
|
Definition
| atypical antipsychotic, no tardic dyskinesia |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| partial seizure drug, calcium blocker |
|
|
Term
|
Definition
| partial seizure drug, calcium blocker |
|
|
Term
|
Definition
| partial seizure drug, calcium blocker |
|
|
Term
|
Definition
| stops GABA transaminase, a break downer of GABA, |
|
|
Term
|
Definition
| inhibit GABA transport, like a DA autoreceptor antagonist |
|
|
Term
|
Definition
| increases GABA in CSF, how is unknown |
|
|
